A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck
- PMID: 4052934
- DOI: 10.1002/1097-0142(19851201)56:11<2573::aid-cncr2820561106>3.0.co;2-u
A phase II study of Adriamycin in previously untreated squamous cell carcinoma of the head and neck
Abstract
Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m2 at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 evaluable tumors. We conclude that Adriamycin is a highly active drug in SCC H/N when no prior treatment has been administered.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials